Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
Rhea-AI Summary
Editas Medicine (Nasdaq: EDIT), a clinical-stage gene editing company, has announced a conference call and webcast scheduled for August 7, 2024, at 8:00 a.m. ET. The event will cover the company's second quarter 2024 results and provide a corporate update. Interested parties can access the call via phone or webcast, with U.S. callers dialing +1-800-343-4849 and international callers using +1-203-518-9848. The webcast will be available on the company's website, and a replay will be accessible approximately one hour after the call concludes.
Positive
- None.
Negative
- None.
News Market Reaction – EDIT
On the day this news was published, EDIT declined 0.18%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a conference call and webcast on Wednesday, August 7, 2024, at 8:00 a.m. ET to discuss results for the second quarter 2024 and to provide a corporate update.
To access the conference call:
- U.S. callers should dial +1-800-343-4849 and international callers should dial +1-203-518-9848 approximately five minutes before the call begins.
- Participants should ask to be connected to the Editas Medicine Earnings Conference Call.
The conference call will also be webcast and can be accessed from the “Investors” section of the Editas Medicine website at https://www.editasmedicine.com. A replay will be available at the same site approximately one hour after the completion of the call.
About Editas Medicine
As a clinical-stage gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.
FAQ
When is Editas Medicine (EDIT) hosting its Q2 2024 earnings call?
How can investors access Editas Medicine's (EDIT) Q2 2024 earnings call?
Will there be a replay available for Editas Medicine's (EDIT) Q2 2024 earnings call?
What topics will be covered in Editas Medicine's (EDIT) upcoming conference call?
